Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

por Rapoport, Aaron P, Stadtmauer, Edward A, Vogl, Dan T, Weiss, Brendan, Binder-Scholl, Gwendolyn K, Smethurst, Dominic P, Finklestein, Jeffrey, Kulikovskaya, Irina, Gupta, Minnal, Brewer, Joanna E, Bennett, Alan D, Gerry, Andrew B, Pumphrey, Nick J, Tayton-Martin, Helen K, Ribeiro, Lilliam, Badros, Ashraf Z, Yanovich, Saul, Akpek, Gorgun, Kerr, Naseem, Philip, Sunita, Westphal, Sandra, Bruce, Levine L, Jakobsen, Bent K, June, Carl H, Kalos, Michael
Publicado 2013

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

por Rapoport, Aaron P., Stadtmauer, Edward A., Binder-Scholl, Gwendolyn K., Goloubeva, Olga, Vogl, Dan T., Lacey, Simon F., Badros, Ashraf Z., Garfall, Alfred, Weiss, Brendan, Finklestein, Jeffrey, Kulikovskaya, Irina, Sinha, Sanjoy K., Kronsberg, Shari, Gupta, Minnal, Bond, Sarah, Melchiori, Luca, Brewer, Joanna E., Bennett, Alan D., Gerry, Andrew B., Pumphrey, Nicholas J., Williams, Daniel, Tayton-Martin, Helen K., Ribeiro, Lilliam, Holdich, Tom, Yanovich, Saul, Hardy, Nancy, Yared, Jean, Kerr, Naseem, Philip, Sunita, Westphal, Sandra, Siegel, Don L., Levine, Bruce L., Jakobsen, Bent K., Kalos, Michael, June, Carl H.
Publicado 2015